Publication Date:
2015-03-13
Description:
Article Resistance to tyrosine kinase inhibitors occurs in treatments of non-small-cell lung cancers (NSCLCs) with EGFR mutations but the mechanisms underlying this acquired resistance are unknown. Here the authors examine the molecular changes that occur in resistant cancers that transition from NSCLC to small-cell lung cancer phenotype and implicate loss of retinoblastoma in this process. Nature Communications doi: 10.1038/ncomms7377 Authors: Matthew J. Niederst, Lecia V. Sequist, John T. Poirier, Craig H. Mermel, Elizabeth L. Lockerman, Angel R. Garcia, Ryohei Katayama, Carlotta Costa, Kenneth N. Ross, Teresa Moran, Emily Howe, Linnea E. Fulton, Hillary E. Mulvey, Lindsay A. Bernardo, Farhiya Mohamoud, Norikatsu Miyoshi, Paul A. VanderLaan, Daniel B. Costa, Pasi A. Jänne, Darrell R. Borger, Sridhar Ramaswamy, Toshi Shioda, Anthony J. Iafrate, Gad Getz, Charles M. Rudin, Mari Mino-Kenudson, Jeffrey A. Engelman
Electronic ISSN:
2041-1723
Topics:
Biology
,
Chemistry and Pharmacology
,
Natural Sciences in General
,
Physics
Permalink